Faculty of Medicine and Health Sciences: Research Development and Support 19 Aug 2019 (#27)

[Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or <a href="www.grants.nih.

Confirm your intent to apply ASAP, but not later than **60 days** before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- CTU NOT-AI-19-066 Notice of Change to Other Attachments in RFA-AI-19-045 "HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required)": Applicants must provide the following additional material specified in this notice for Attachments 1 and 2. Attachment 3 is optional. Each attachment should be uploaded as a separate PDF using the indicated filenames (which will serve as application bookmarks).
- NOT-AG-19-033 Notice of Special Interest: Selective Cell and Network Vulnerability in Aging and Alzheimers Disease
- NOT-DA-19-065 Notice of Special Interest (NOSI): Public Health Research on Cannabis
- NOT-HL-19-712 Notice of Special Interest (NOSI): IDEA2Health: Innovative Data Evaluation and Analysis to Health (Parent R01 Clinical Trial Not Allowed)
- Upcoming Deadlines
 - Fogarty HIV Research Training Program: 20 Aug 2019
 - Global Brain and Nervous System Disorders Research Across the Lifespan: 7 Nov 2019
 - Emerging Global Leader Award: 7 Nov 2019
 - Chronic, Noncommunicable Diseases and Disorders Research Training: 12 Nov 2019
 - Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs: 12 Nov 2019
 - Ecology and Evolution of Infectious Diseases (EEID): 20 Nov 2019
 - Global Noncommunicable Diseases and Injury Research: 13 December 2019

NIH funding opportunities for which United States small business concerns (SBCs) may collaborate with a foreign business entity.

 Technologies to Advance Precision Medicine Diagnosis and Treatment of Infertility, Reproductive Tract and Gynecologic Disorders Affecting Fertility (R43/R44 Clinical Trial Optional) (RFA-HD-20-010) Application Receipt Date(s): December 3, 2019

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date Hyperlink: PAR-19-339 Type: R21

Application Due Date: October 9, 2019; June 10, 2020; October 14, 2020; June 9, 2021; October 13, 2021; June 8, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

2. Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date Hyperlink: PAR-19-340 Type: R01

Application Due Date: October 9, 2019; June 10, 2020; October 14, 2020; June 9, 2021; October 13, 2021; June 8, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years

3. Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date Hyperlink: PAR-19-344 Type: R01

Application Due Date: March 10, 2020, March 10, 2021, March 10, 2022. Apply by 5:00 PM local time of applicant organization. **Funding Opportunity Announcement:** Explainable Artificial Intelligence (XAI) aims to provide strong predictive value along with mechanistic understanding of AI by combining machine learning techniques with effective explanatory techniques. This Funding Opportunity Announcement (FOA) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This FOA encourages collaborations between computationally and experimentally-focused investigators. This FOA seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date Hyperlink: PAR-19-346 Type: I

Application Due Date: The first standard due date for this FOA is October 16, 2019 and then <u>Standard dates</u> apply. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.

Budget: Direct costs are limited to \$275,000 over the two-year project period, with no more than \$200,000 in direct costs allowed in any single year.

5. Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: PAR-19-347

Type: R03

Application Due Date: The first standard due date for this FOA is October 16, 2019 and then <u>Standard dates</u> apply. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.

Budget: A budget for direct costs of up to \$50,000 per year may be requested (i.e. a maximum of \$100,000 over two years)

Brief definitions of some NIH grant mechanisms: comprehensive list of extramural grant and cooperative agreement activity codes

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University

5th Floor, Teaching Block, Tygerberg Campus.

Enquiries: Christa

e: cdevries@sun.ac.za | t: +27 21 938 9838